Odes Shmuel, Greenberg Dan
Department of Gastroenterology and Hepatology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
Department of Health Systems Management, Faculty of Health Sciences and Guilford Glazer Faculty of Business and Management, Ben-Gurion University of the Negev, Beer Sheva, Israel.
Clinicoecon Outcomes Res. 2014 Oct 8;6:431-43. doi: 10.2147/CEOR.S39212. eCollection 2014.
The treatment of inflammatory bowel disease with standard therapy fails to control the disease in many patients. Biologic therapy has an increasing role in altering the natural history of Crohn's disease and ulcerative colitis, and is improving patient prognosis. However, indications for treatment and issues with drug costs and value for money remain unclear. Also, when to perform early intervention with biologic agents is at present unclear. We performed an extensive literature search and review to address these issues. The biologics provide better care for many patients. The choice of biologic agent, the indications for its use, the switch between agents, and the considerations of cost are outlined, with a view to guiding the treating physician in managing these cases. Outstanding issues and anticipated future developments are defined.
在许多患者中，采用标准疗法治疗炎症性肠病无法控制病情。生物疗法在改变克罗恩病和溃疡性结肠炎的自然病程方面发挥着越来越重要的作用，并正在改善患者的预后。然而，治疗指征以及药物成本和性价比问题仍不明确。此外，目前尚不清楚何时使用生物制剂进行早期干预。我们进行了广泛的文献检索和综述以解决这些问题。生物制剂为许多患者提供了更好的治疗。本文概述了生物制剂的选择、使用指征、制剂间的转换以及成本考量，旨在指导治疗医生处理这些病例。明确了突出问题和预期的未来发展方向。
